ASCO 2016 - update colorectal liver metastases

Area of Science:

• Oncology
• Gastroenterology
• Surgical Oncology

Background:

• Colorectal liver metastases (CLM) represent a significant challenge in cancer treatment.
• Optimal management strategies for CLM vary based on resectability.
• Advances in systemic therapy and surgical techniques continue to evolve.

Purpose of the Study:

• To review key findings on colorectal liver metastases (CLM) from the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting.
• To categorize CLM management based on resectability: upfront resectable, borderline resectable, and unresectable.
• To highlight recent data on surgical techniques and systemic therapies for CLM.

Main Methods:

• Review of congress abstracts presented at the 2016 ASCO Annual Meeting focusing on CLM.
• Categorization of studies into three clinical scenarios: upfront resectable, borderline resectable, and unresectable CLM.
• Analysis of data from registry studies, prospective noninterventional studies, and phase 2 trials.

Main Results:

• For upfront resectable, solitary CLM, parenchymal sparing resection is advised.
• Chemotherapy combined with bevacizumab (anti-VEGF antibody) demonstrated efficacy and tolerability in borderline resectable CLM.
• In unresectable CLM, FOLFIRINOX plus a targeted agent yielded superior resection rates and overall survival (OS) compared to FOLFIRI or FOLFOX4 regimens.
• Tailoring first-line chemotherapy based on TYMS and ERCC1 polymorphisms improved response rates, progression-free survival (PFS), and OS.

Conclusions:

• Surgical approach for CLM should be tailored, favoring parenchymal sparing techniques for early-stage disease.
• Combination therapy with bevacizumab is a viable option for borderline resectable CLM.
• Novel chemotherapy regimens like FOLFIRINOX offer improved survival benefits for unresectable CLM.
• Personalized chemotherapy based on genetic polymorphisms can enhance treatment outcomes in CLM patients.